Search results for "European Union."

showing 10 items of 1334 documents

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

2018

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in…

0301 basic medicineMalePediatricsEpidemiologyvirusesInfluenza B viruinfluenza ; influenza vaccine effectiveness ; influenza vaccination ; case control study ; multicentre study ; EuropeEurope case control study influenza influenza vaccination influenza vaccine effectiveness multicentre study0302 clinical medicineInfluenza A Virus H1N1 Subtype[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInteriminfluenza vaccine effectivenessEpidemiologyPandemicInfluenza A Virus030212 general & internal medicineQAInfluenza vaccine effectivenessChildmedia_commonVaccine EffectivenessVaccinationvirus diseasesMiddle Agedinfluenza vaccinationmulticentre study3. Good healthVaccinationEuropeTreatment OutcomeInfluenza VaccinesChild PreschoolH3N2 SubtypeFemaleSeasonsInfluenza VaccineinfluenzaRapid CommunicationHumanAdultRMmedicine.medical_specialtyAdolescentInfluenza vaccine030106 microbiologyCase control studyMulticentre studyEuropean studiesSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA03 medical and health sciencesVirologyInfluenza Humanmedicinemedia_common.cataloged_instanceHumansH1N1 SubtypeVacina AntigripalEuropean UnionEuropean unionPreschoolPandemicsAgedPandemicInfluenza A Virus H3N2 SubtypeCuidados de SaúdePublic Health Environmental and Occupational HealthInfant NewbornInfantInfluenza ainfluenza vaccine effectivenecase control studyNewbornEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre studyInfluenzarespiratory tract diseasesInfluenza vaccinationInfluenza B virusEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study; Adolescent; Adult; Aged; Child; Child Preschool; Europe; European Union; Female; Humans; Infant; Infant Newborn; Influenza A Virus H1N1 Subtype; Influenza A Virus H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza Human; Male; Middle Aged; Pandemics; Treatment Outcome; Vaccination; Seasons[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDeterminantes da Saúde e da Doença[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
researchProduct

Case-based surveillance of measles in Sicily during 2012-2017: The changing molecular epidemiology and implications for vaccine strategies.

2018

Following the indication of the World Health Organization, a national plan for the elimination of measles was approved in Italy and this included the improvement of the molecular surveil- lance of measles viruses and the interruption of indigenous transmission of the disease. Nevertheless, large outbreaks continue to occur in almost all regions of the country, includ- ing Sicily. Here we describe the epidemiology and molecular dynamics of measles viruses as a result of the measles surveillance activity carried out by the “Reference Laboratory for Measles and Rubella” in Sicily over a 5-year period. Biological samples of 259 suspected measles cases were tested for viral RNA detection and a t…

0301 basic medicineMaleRNA virusesViral DiseasesHeredityMeasles Surveillance Vaccine Epidemiology Molecular epidemiology Genotyping Sicily Italylcsh:MedicineSettore MED/42 - Igiene Generale E ApplicataPathology and Laboratory MedicineGeographical locationsEpidemiologyMedicine and Health SciencesPublic and Occupational HealthChildlcsh:ScienceSicilyData ManagementMolecular EpidemiologyMultidisciplinarybiologyTransmission (medicine)Database and informatics methodsSequence analysisPhylogenetic AnalysisVaccination and ImmunizationPhylogeneticsEuropeGenetic MappingInfectious DiseasesItalyMedical MicrobiologyChild PreschoolViral PathogensVirusesRNA ViralPathogensResearch ArticleAdultmedicine.medical_specialtyComputer and Information SciencesAdolescentBioinformaticsMeasles VaccineImmunologyNucleotide SequencingMeasles VirusVariant GenotypesRubellaMeaslesMicrobiologyMeasles virus03 medical and health sciencesYoung AdultmedicineGeneticsHumansEvolutionary SystematicsEuropean UnionMolecular Biology TechniquesSequencing TechniquesGenotypingMicrobial PathogensMolecular BiologyDNA sequence analysisRetrospective StudiesTaxonomyEvolutionary BiologyMolecular epidemiologyBiology and life scienceslcsh:ROrganismsOutbreakInfantbiology.organism_classificationmedicine.diseaseVirologyResearch and analysis methods030104 developmental biologyParamyxoviruseslcsh:QPreventive MedicinePeople and placesMeaslesPLoS ONE
researchProduct

Anisakis sensitization in different population groups and public health impact. A systematic review

2018

Anisakis simplex spp. sensitization rates have increased worldwide, with a significant impact on health-care systems. To date, no clear-cut diagnostic criteria and laboratory algorithm have been established, so anisakiasis still represents an under-reported health problem whose clinical manifestations, when present, mimic the much more common allergic and digestive disorders. Aim of the study was to systematically review the available literature on the prevalence of sensitization against Anisakis in the general population and in specific population groups, taking into account the impact of the different available diagnostic techniques on the epidemiological data. Following the Preferred Rep…

0301 basic medicineNematodaUrticarialcsh:MedicineSettore MED/42 - Igiene Generale E ApplicataAnisakisGeographical locations0302 clinical medicineAllergiesEpidemiologyMedicine and Health SciencesantibodiesEnzyme-Linked Immunoassayslcsh:SciencehumanshelminthSensitizationeducation.field_of_studyMultidisciplinaryAllergic DiseasesbiologyShellfish allergyEukaryotaanimals; anisakis; antibodies helminth; enzyme-linked immunosorbent assay; humans; hypersensitivity; occupational exposureClinical Laboratory SciencesEuropeanimalsClinical Laboratoriesmedicine.anatomical_structureSystematic reviewhypersensitivityResearch Articlemedicine.medical_specialtyImmunologyImmunoblotting030231 tropical medicinePopulationFood AllergiesAntibodies HelminthMolecular Probe TechniquesDermatologyResearch and Analysis Methods03 medical and health sciencesDiagnostic MedicineEnvironmental healthmedicineEuropean UnionImmunoassaysMolecular Biology TechniqueseducationMolecular BiologyBiochemistry Genetics and Molecular Biology (all)business.industryPublic healthlcsh:RAnisakis simplexOrganismsBiology and Life Sciencesoccupational exposureanisakismedicine.diseasebiology.organism_classificationInvertebrates030104 developmental biologyAgricultural and Biological Sciences (all)SpainImmunologic TechniquesClinical Immunologylcsh:Qenzyme-linked immunosorbent assayClinical MedicinePeople and placesbusiness
researchProduct

High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial

2018

Background: Patients with extremity and trunk wall soft tissue sarcoma (STS) with high malignancy grade and size >5 cm are at high-risk of death. This risk varies depending also on other patient and tumour features, including histologic subtype. This study investigated whether a prognostic nomogram can improve risk assessment of these patients. Methods: Data from high-risk STS patients enrolled in a randomised controlled trial investigating different perioperative chemotherapy regimens were analysed. Ten-year probability of overall survival (OS) and incidence of distant metastasis (DM) were computed using the prognostic nomogram Sarculator (pr-OS and inc-DM, respectively). Tumour response a…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyCancer ResearchAdolescentTumour responsePerioperative Care03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOutcome Assessment Health Caremedicinemedia_common.cataloged_instanceHumansChemotherapyEuropean unionSurvival ratemedia_commonAgedSoft tissue sarcomabusiness.industryChemotherapy; Choi criteria; Neoadjuvant; Prognosis; Soft tissue sarcoma; Tumour response; Oncology; Cancer ResearchSoft tissue sarcomaIncidence (epidemiology)SarcomaNomogramMiddle Agedmedicine.diseasePrognosisClinical trialSurvival RateNomograms030104 developmental biologyChoi criteriaOncology030220 oncology & carcinogenesisFemaleSarcomaNeoadjuvantRisk assessmentbusinessFollow-Up Studies
researchProduct

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the Europe…

2020

Background Irreversible sensorineural hearing loss is a common side effect of platinum treatment with the potential to significantly impair the neurocognitive, social and educational development of childhood cancer survivors. Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in the FDA drug label and a pharmacogenetic guideline. The aim of this cross-sectional cohort study was to confirm the genetic associations in a large pan-European population and to evaluate the diagnostic accuracy of the genetic…

0301 basic medicineOncologyMaleCancer ResearchCandidate genePharmacogenomic VariantsCancer survivorsCHILDRENAnti-neoplastic drugsVARIANTSOCT2Carboplatin0302 clinical medicineHearingRisk FactorsNeoplasmsTPMTHearing / drug effectsProspective StudiesAge of OnsetChild610 Medicine & healthPREDICTORSmedia_commonHearing Loss Sensorineural / physiopathologyeducation.field_of_studyddc:618Thiopurine methyltransferasebiologycarboplatin [Cisplatin]Neoplasms / drug therapyOrganic Cation Transporter 2EuropeOncologyCisplatin: carboplatinCisplatin / adverse effects030220 oncology & carcinogenesisChild PreschoolOrganic Cation Transporter 2 / geneticsFemaleSENSITIVITYChildhood cancer360 Social problems & social servicesCohort studyDrug-induced ototoxicitymedicine.medical_specialtyINDUCED HEARING-LOSSAdolescentMulticenter cohort studyHearing Loss SensorineuralPopulationAdverse drug reactionAntineoplastic AgentsPolymorphism Single NucleotideRisk AssessmentHearing Loss Sensorineural / chemically inducedCarboplatin / adverse effects03 medical and health sciencesACYP2OtotoxicitySDG 3 - Good Health and Well-beingInternal medicinemedicineGenetic predispositionmedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseCISPLATIN-INDUCED OTOTOXICITYEuropean unioneducationGenetic Association StudiesGenetic associationRetrospective Studiesbusiness.industryAntineoplastic Agents / adverse effectsInfant NewbornInfantOdds ratioGuidelinemedicine.diseaseOtotoxicityCOMTPharmacogenomic Testing030104 developmental biologyCross-Sectional StudiesPharmacogeneticsbiology.proteinGenetic markersHearing Loss Sensorineural / geneticsCisplatinbusinessPharmacogenetics
researchProduct

The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency

2017

International audience; A good understanding of the natural history of rare genetic lipid disorders is a pre-requisite for successful patient management. Disease registries have been helpful in this regard. Lipoprotein Lipase Deficiency (LPLD) is a rare, autosomal-recessive lipid disorder characterized by severe hypertriglyceridemia and a very high risk for recurrent acute pancreatitis, however, only limited data are available on its natural course. Alipogene tiparvovec (Glybera (R)) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL (GENetherapy In the MAnagement of Lipoprotein Lipase Deficiency), a 15-year registry focusing on LPLD was launched in …

0301 basic medicinePediatricsPathologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]Familial hypercholesterolemiaDisease030204 cardiovascular system & hematologyGeneTHERAPY0302 clinical medicineFamilialRisk FactorsHyperchylomicronemiaAlipogene tiparvovecRegistriesFAMILIAL HYPERCHOLESTEROLEMIAmedia_commonHypertriglyceridemiaPrognosis3. Good healthNatural historySystematic reviewPhenotypeDISEASESSAFETYHyperlipoproteinemia Type ICardiology and Cardiovascular Medicinemedicine.medical_specialtyAPHERESISRegistryFamilial chylomicronemia syndromeGENIALLLysosomal acid lipase deficiencyLipid Metabolism Inborn Errors03 medical and health sciencesLipoprotein lipase deficiencyRare DiseasesGene therapychylomicronemia syndromemedicinemedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseEuropean unionLipoprotein lipase deficiency (LPLD)business.industryALIPOGENE TIPARVOVEC AAV1-LPLS447Xmedicine.diseaseAlipogene tiparvovecLipoprotein Lipase030104 developmental biologyOrphan diseasebusiness
researchProduct

Sentinel hospital-based surveillance for norovirus infection in children with gastroenteritis between 2015 and 2016 in Italy

2018

Noroviruses are one of the leading causes of gastro-enteric diseases worldwide in all age groups. Novel epidemic noroviruses with GII.P16 polymerase and GII.2 or GII.4 capsid type have emerged worldwide in late 2015 and in 2016. We performed a molecular epidemiological study of the noroviruses circulating in Italy to investigate the emergence of new norovirus strains. Sentinel hospital-based surveillance, in three different Italian regions, revealed increased prevalence of norovirus infection in children (<15 years) in 2016 (14.4% versus 9.8% in 2015) and the emergence of GII.P16 strains in late 2016, which accounted for 23.0% of norovirus infections. The majority of the strains with a GII.…

0301 basic medicineRNA virusesEuropean PeopleSettore MED/07 - Microbiologia E Microbiologia Clinicavirusesmedicine.disease_causePathology and Laboratory MedicinePediatricsGeographical locationsfluids and secretionsEpidemiologyGenotypePrevalenceMedicine and Health SciencesEthnicitiesChildCaliciviridae InfectionsMultidisciplinaryIncidence (epidemiology)Database and informatics methodsQRSequence analysisvirus diseasesGastroenteritisItalian PeopleEuropeCapsidItalyMedical MicrobiologyChild PreschoolViral PathogensVirusesMedicineRNA ViralPathogensPediatric InfectionsResearch Articlemedicine.medical_specialtyGenotypingGenotypeBioinformaticsScience030106 microbiologySequence DatabasesMicrobiologyCaliciviruses03 medical and health sciencesAge groupsmedicineHumansEuropean UnionMolecular Biology TechniquesGenotypingMicrobial PathogensMolecular BiologyBiochemistry Genetics and Molecular Biology (all)RNA sequence analysisBiology and life sciencesbusiness.industrySequence Analysis RNANorovirusOrganismsGenetic VariationRNA-Dependent RNA PolymeraseVirologydigestive system diseasesResearch and analysis methods030104 developmental biologyCaliciviridae InfectionsBiological DatabasesAgricultural and Biological Sciences (all)NorovirusCapsid ProteinsPopulation GroupingsPeople and placesbusinessSentinel Surveillance
researchProduct

Corrigendum to “European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS…

2018

The European Cooperation in Science and Technology (COST) provides an ideal framework to establish multi-disciplinary research networks. COST Action BM1203 (EU-ROS) represents a consortium of researchers from different disciplines who are dedicated to providing new insights and tools for better understanding redox biology and medicine and, in the long run, to finding new therapeutic strategies to target dysregulated redox processes in various diseases. This report highlights the major achievements of EU-ROS as well as research updates and new perspectives arising from its members. The EU-ROS consortium comprised more than 140 active members who worked together for four years on the topics b…

0301 basic medicineSocieties ScientificRedox signalingInternational CooperationClinical BiochemistryNanotechnologyReview ArticleBiologyPublic administrationBiochemistryAntioxidantsArticle03 medical and health sciencesmedia_common.cataloged_instanceAnimalsHumansCost actionEuropean UnionEuropean unionMolecular Biologylcsh:QH301-705.5media_commonFunding AgencyRedox therapeuticslcsh:R5-920Organic ChemistryReactive nitrogen species030104 developmental biologyWork (electrical)lcsh:Biology (General)Oxidative stressReactive Oxygen Specieslcsh:Medicine (General)Oxidation-ReductionSignal TransductionRedox Biology
researchProduct

Exposure to Perfluoroalkyl Substances and Metabolic Outcomes in Pregnant Women: Evidence from the Spanish INMA Birth Cohorts

2017

BACKGROUND: Exposure to perfluoroalkyl substances (PFASs) may increase risk for metabolic diseases; however, epidemiologic evidence is lacking at the present time. Pregnancy is a period of enhanced tissue plasticity for the fetus and the mother and may be a critical window of PFAS exposure susceptibility. OBJECTIVE: We evaluated the associations between PFAS exposures and metabolic outcomes in pregnant women. METHODS: We analyzed 1,240 pregnant women from the Spanish INMA [Environment and Childhood Project (INfancia y Medio Ambiente)] birth cohort study (recruitment period: 2003-2008) with measured first pregnancy trimester plasma concentrations of four PFASs (in nanograms/milliliter). We u…

0301 basic medicinemedicine.medical_specialtyC-reactive protein/metabolismHealth Toxicology and Mutagenesis010501 environmental sciences01 natural sciencesCohort Studies03 medical and health sciencesEmbarassadesFluorocarbons/bloodPregnancyEnvironmental healthGlucose IntoleranceHumansmedia_common.cataloged_instanceMedicineEuropean unionAlkanesulfonic acids/bloodEnvironmental pollutants/blood0105 earth and related environmental sciencesmedia_commonFluorocarbonsbusiness.industryObstetricsResearchPregnant womenPublic Health Environmental and Occupational HealthHispanic or LatinoUniversity hospitalMetabolisme3. Good healthDiabetes GestationalC-Reactive Protein030104 developmental biologyMetabolismAlkanesulfonic AcidsCaprylates/bloodEnvironmental PollutantsFemaleMaternal exposureChristian ministryCaprylatesbusinessBirth cohortCohort study
researchProduct

Mineral essential elements for nutrition in different chocolate products

2016

In this work, the essential mineral nutritional elements in cocoa beans, in chocolates at different cocoa percentage (60,70,80 and 90%) and in milk chocolate are evaluated. Dark chocolates are confirmed as an excellent source of magnesium (252.2 mg/100 g) and iron (10.9 mg/100 g): in chocolate containing 90% cocoa, their content corresponds to, respectively, 67.0% and 80.3 of Nutrient Reference Values (NRV) in the European Union. The chocolate containing 90% cocoa is also a good source of zinc (3.5 mg/100 g), which is important for the immune system, and selenium (0.1 mg/100 g). Three main components suitable to explain the mineral concentrations are analyzed by factor analysis. The compone…

0301 basic medicinemineralFood HandlingIronDietarychemistry.chemical_elementZincmagnesiumFood handlingSelenium03 medical and health sciences0302 clinical medicineNutrientmedia_common.cataloged_instance030212 general & internal medicineFood scienceChocolate; cocoa; iron; magnesium; mineral; nutritional values; Cacao; Chocolate; Iron Dietary; Magnesium; Selenium; Trace Elements; Zinc; Food Handling; Nutritive Value; Food ScienceChocolateEuropean unionTrace Elementmedia_commonnutritional valueCacao030109 nutrition & dieteticsMineralSettore AGR/15 - Scienze E Tecnologie AlimentariTrace ElementsZincMilk ChocolatechemistrycocoaReference valuesnutritional valuesNutritive ValueIron DietarySeleniumFood ScienceInternational Journal of Food Sciences and Nutrition
researchProduct